Mizuho initiated coverage of Maze Therapeutics (MAZE) with an Outperform rating and $97 price target The firm says Maze’s first two drug candidate programs, MZE829 and MZE782, have high revenue “potency.” It models $8B of peak revenue for thee two programs combined. This “could potentially allow for disproportionate value creation” over the next 5-10 years, the analyst tells investors in a research note.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MAZE:
- Underappreciated Cardiometabolic Upside: Validating Maze’s SLC6A19 Inhibitor MZE782 and Supporting a Buy on MAZE
- Buy Rating on Maze Therapeutics: Favorable HORIZON Phase 2 Setup, Validated APOL1 Biology, and Underappreciated Pipeline Upside
- Maze Therapeutics price target raised to $58 from $46 at Guggenheim
- Buy Rating on Maze Therapeutics Driven by MZE829’s Differentiated APOL1 Mechanism and HORIZON UACR-Reduction Catalyst
- Maze Therapeutics files automatic mixed securities shelf